News and perspective in management of high-risk prostate cancer - Abstract

Service d'Urologie Hôpital Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Groupe Hospitalo-Universitaire Est, Faculté de médecine Pierre et Marie Curie, Université Paris VI, Paris, France.

 

Advanced prostate cancers include situations involving the patient's survival in the medium or short run. They are responsible for the second leading cause of death by cancer in France. However, their management is poorly codified and confronts clinicians and researchers to therapeutic problems. Even if the main options remain surgery radiotherapy and hormone therapy, alone or in combination, their places tends to be clarified. The association radio-hormonotherapy is the gold standard, but surgery first has interesting results with the possibility of multi-modal salvage treatment if necessary. Similarly, improved diagnostic tools allow a more personal management of these patients and the search for predictive factors (early PSA assay, time to reach PSA nadir) contribute to provide better monitoring. The mortality of prostate cancer decreases by 2.5 % per year due to earlier detection of cancer and advances in treatment of advanced forms. Technical advances in surgery and radiotherapy, associated with new ways of androgeno-suppression should continue this trend.

Article in French.

Written by:
Audenet F, Rouprêt M.   Are you the author?

Reference: Prog Urol. 2011 May;21 Suppl 3:S80-3.
doi: 10.1016/S1166-7087(11)70018-5

PubMed Abstract
PMID: 21616444

UroToday.com Prostate Cancer Section

 

 

email news signup